Editor’s take – health care and life sciences: Bumpy pandemic progress, an Alzheimer’s drug that may not help and worries for the future

The reading habits of SmartBrief’s health care and life sciences audiences provide a unique window into the priorities and interests of professionals across these industries, and our newsletter engagement data also sheds light on what’s keeping our readers up at night. We serve health care insurers, clinicians and IT professionals, as well as audiences in pharma and medtech. Here’s what was top of mind for all of them in Q2, as well as a look at what’s next.

Read the source article at SmartBrief
2021-07-26 13:54:02